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Does female gender or hormone replacement
therapy affect early or late outcome after carotid
endarterectomy?
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Objective: Subgroup analyses of the Asymptomatic Carotid Atherosclerosis Study and the North American Symptomatic
Carotid Endarterectomy Trial trials have questioned the ability of carotid endarterectomy (CEA) to reduce the risk of
stroke in women. The purpose of this study was to test the effect of female gender and estrogen-based hormone
replacement therapy on perioperative (30-day) and long-term (5-year) outcomes after CEA.
Methods: From 1988 to 1998, 361 CEAs were performed in 326 patients (246 male, 115 female) by a single surgeon.
Retrospective data were collected with chart review, and follow-up data were obtained with clinical examination or
telephone interview. Follow-up was possible in 95% of patients. Reoperative CEAs and combined aortic or cardiac
procedures were excluded. Statistical analysis used life-table methods, Student t test, and Pearson 2 tests when
appropriate.
Results: Age and preoperative risk factors were similar between women and men. CEA was performed for symptomatic
(50% female, 42% male) and asymptomatic carotid stenosis (50% female, 58% male; P  .19). Perioperative (30-day)
stroke rate was similar for women and men (3.6% female, 1.2% male; P  .13). No perioperative strokes occurred in
asymptomatic patients. With previous stroke or transient ischemic attack, a trend was seen towards an increased
perioperative stroke rate in women (7.0% female, 2.8% male; P .25). Long-term follow-up showed a similar trend in the
5-year stroke rate in symptomatic patients (7.0% female, 2.8 male; P  .23). The stroke-free survival rate was not
significantly different between genders (87% female, 75% male; P  .58). Reoperation was performed for asymptomatic
recurrent carotid stenosis in five men (2.3%) and two women (1.9%; P  .84). Interestingly, the use of estrogen-based
hormone replacement therapy in women showed a trend toward increasing stroke rate at 30 days (1.2% versus 8.7%; P 
.08) and at 5 years (2.3% versus 8.7%; P  .16).
Conclusion: This retrospective study confirms that CEA provides long-term reduction in stroke risk and improved
stroke-free survival rates in both men and women. However, women with previous neurologic symptoms and those using
hormone replacement therapy appear to be at higher stroke risk at the time of surgery. (J Vasc Surg 2003;37:568-74.)
The benefit of carotid endarterectomy (CEA) in the
reduction of stroke risk has been rigorously proven in
randomized control trials for both symptomatic1,2 and
asymptomatic3 patients. However, controversy exists as to
whether female patients enjoy the same stroke risk reduc-
tion as do male patients. In both the Asymptomatic Carotid
Atherosclerosis Study (ACAS) and the North American
Symptomatic Carotid Endarterectomy Trial (NASCET),
although CEA was shown to be beneficial in the overall
reduction of stroke risk, subgroup analysis showed that
men generally fared better than women. The results of
these post hoc analyses did not reach statistical significance
nor were the studies designed to detect gender differences.
However, these observations have spurred considerable
debate and have fueled a number of surgeons to investigate
their own experience with respect to gender-related issues.
In a recent metaanalysis of retrospective studies,4 female
gender was associated with a 44% increased odds ratio of
stroke and death after CEA.
Recent controversy has also been seen involving the risk
of stroke in women undergoing postmenopausal hormone
replacement therapy (HRT). A large proportion of post-
menopausal women are placed on HRT to alleviate meno-
pausal symptoms and because of its primary preventative
effect in the treatment of osteoporosis and coronary artery
disease.5,6 However, recent studies have called the routine
use of HRT into question. In a large randomized con-
trolled trial in women,7 HRT was associated with an in-
creased frequency of coronary and thromboembolic events
in patients with preexisting coronary vascular disease. In
addition, in a recent prospective randomized study in
healthy postmenopausal women, the use of estrogen plus
progestin HRT was halted because of an increased inci-
dence rate of breast cancer, cardiovascular events, and
stroke.8 In the surgical literature, the use of HRT has also
been shown be detrimental to the patency rates after fem-
oral-popliteal bypass grafting.9 The effect of HRT use in
women undergoing CEA has yet to be explored.
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The purpose of this retrospective study was to examine
gender-related issues in the outcome after CEA. We at-
tempted to compare differences in stroke rate and stroke-
free survival (SFS) rate between men and women who have
undergone CEA. In addition, we examined the use of
estrogen-based HRT among the subgroup of female pa-
tients in our study. Because close follow-up of patients after
CEA was available, both perioperative and 5-year outcomes
are reported.
METHODS
The study design was a retrospective chart review with
follow-up data collected with telephone interview or clini-
cal examination.
Patients. From 1988 to 1998, 361 CEAs were per-
formed in 326 patients by a single surgeon. Operations
performed in male patients (n  246; 68%) outnumbered
those in female patients (n  115; 32%) by more than 2:1.
All procedures were performed in a tertiary referral univer-
sity-based medical center. Retrospective data were ex-
tracted from outpatient charts and entered into a computer
database. Patient characteristics were collected pertinent to
risk factors for atherosclerotic disease, cardiac comorbidity,
chronic renal failure, and chronic obstructive pulmonary
disease. The use of HRT was also determined for female
patients at the time of surgery. HRT was defined as the use
of estrogen-based or estrogen/progestin combination
drug therapy. The use of other medications with mild
estrogenic effects, such as Tamoxifen (AstraZeneca, Wil-
mington, Del) or Reloxifen (Eli Lilly, Indianapolis, Ind)
was excluded.
Operations. Carotid endarterectomy was offered on
the basis of established criteria from randomized control
trials.1,2 Degree of carotid stenosis was based on duplex
scan criteria alone in most patients, as determined by Uni-
versity of Washington standards.10 Additional radiologic
tests were performed when clinically indicated. Only pa-
tients undergoing initial surgical intervention for carotid
stenosis were considered in this series to ensure a uniform
patient population. All procedures performed for carotid
restenosis, total carotid occlusion, external CEA, and com-
bined cardiac or aortic procedures were excluded.
Follow-up. Data were collected for long-term out-
come analysis with telephone interview or with clinical
examination by the operating surgeon. This practice is in
accordance with Society for Vascular Surgery/Interna-
tional Society for Cardiovascular Surgery reporting stan-
dards.11 Complete follow-up was possible in 95% of oper-
ated patients.
Confirmation of stroke was defined as any ipsilateral
neurologic deficit in the postoperative period that lasted
more than 24 hours. Proof of survival was determined with
telephone interview or at the time of last clinical examina-
tion. Mortality was also determined with telephone contact
of surviving relatives and was confirmed with registry in the
Social Security Death database.
Statistical analysis. Data analysis conformed to Soci-
ety for Vascular Surgery/International Society for Cardio-
vascular Surgery reporting standards.11 All statistical tests
were performed with the assistance of a university-based
statistician. Computations were completed with SAS statis-
tical software, version 6.11 (SAS Institute, Cary, NC).
Univariate comparison of patient characteristics was
determined with a 2  2 table method. Continuous vari-
ables were compared with a two-tailed Student t test.
Categoric variables were compared with 2 test. Fischer
exact test was used when smaller than expected frequencies
were encountered.
Life tables were constructed for stroke rates for men
and women and also for subgroup analysis of symptomatic
and asymptomatic patients. Similar life tables were con-
structed comparing women with HRT with those without.
Comparisons of stroke rates were performed at 30 days
with 2 test and at 5 years with the log-rank test.
Kaplan-Meier SFS curves were prepared with computer
graphics to 160 months after surgery. The probability of
SFS was estimated at 30 days and 5 years, and comparison
of SFS curves used the log-rank technique. Significance was
assumed for all tests at a P value of less than .05.
RESULTS
Patient characteristics. Table I summarizes the char-
acteristics of patients undergoing CEA. CEA was per-
formed more frequently in male patients (n  246; 68%)
than in female patients (n  115; 32%) in our series. CEA
was performed in female patients with equal frequency for
symptomatic and asymptomatic carotid stenosis (50%). In
male patients, a slightly higher proportion underwent CEA
for asymptomatic stenosis (58%) than for symptomatic
disease (42%). This difference did not reach statistical sig-
nificance (P  .194).
The average age at the time of operation was similar
between the genders (female, 72.6 years; versus male, 70.9
years; P  .104). Risk factors for atherosclerosis were
comparable between female and male patients. Men were
more likely to have a history of smoking, diabetes mellitus,
and myocardial infarction, and women were more likely to
have hypertension and congestive heart failure. These dif-
ferences also did not reach statistical significance (P .05).
Other major comorbidities, such as chronic renal failure
and chronic obstructive pulmonary disease, were present in
a minority of patients.
Carotid duplex scanning was performed in 95% of
patients, angiography in 8%, and magnetic resonance an-
giography in 3%. No preoperative strokes occurred in this
series as a result of preoperative angiography. No carotid
angioplasty or stenting procedures were attempted.
CEA was performed for asymptomatic stenosis (80% to
99% with duplex scanning) in 58 women (50%) and 142
men (58%). Operations were performed in symptomatic
patients in 57 women (50%) and 104 men (42%). Symp-
toms consisted of preoperative stroke in 18 women (16%)
and 36 men (14%). Transient ischemic attacks (TIAs) oc-
curred in 39 women (34%) and 68 men (28%).
Operative technique. Table I summarizes character-
istics of the operation. General anesthesia was used in 100%
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of the cases. Most cases were performed with electroen-
cephalographic monitoring (85% female, 89% male; P 
.413). Shunting was performed selectively on the basis of
intraoperative changes in electroencephalographic pat-
terns. Shunts were placed in roughly one third of the cases
(33% female, 30% male; P  .667). An evolution toward
routine prosthetic patching occurred over the study period,
with patches placed in an equivalent proportion of male and
female patients (89%; P  .9). Tacking sutures were rarely
used for uneven distal endpoints and were only used in two
male patients (P  .9). Completion studies consisted of
intraoperative angiogram in 97% of patients and intraoper-
ative duplex scan in 3%.
Perioperative outcome. Perioperative stroke was de-
fined as any ipsilateral neurologic deficit that occurred
within 30 days of operation and persisted for more than 24
hours. Perioperative strokes occurred in four female pa-
tients (3.6%) and three male patients (1.2%; P .13). This
stroke rate is below the institution threshold recommended
by the consensus statement of the American Heart Associ-
ation.12 No perioperative strokes occurred in previously
asymptomatic patients (0%; P  not significant). This
yielded a 30-day stroke rate for symptomatic patients of
2.8% in men and 7.0% in women (P  .245).
Perioperative deaths occurred in two men and three
women. The cause of death was attributed to cardiac de-
compensation (two male, one female), respiratory failure
(one female) and intraoperative stroke (one female).
Long-term outcome. Follow-up data were available
for 95%of patients undergoing CEA. The mean follow-up
interval was 51  2 months (4 years). This is the longest
reported follow-up interval among retrospective studies
after CEA.13-17
Long-term results confirmed CEA to be a durable
procedure for stroke prevention. The cumulative 5-year
stroke rate was 3.6% for women and 2.0% in men (P 
.474; Table II, online only). This represents the occur-
rence of two new ipsilateral strokes in male patients
outside the perioperative period and no new strokes in
female patients. Among previously asymptomatic pa-
tients, the 5-year stroke rate was 0% for women and 1.4%
for men (P .9), representing two new ipsilateral strokes
in men (Table III, online only). Patients undergoing
CEA for previous stroke or TIA had no new strokes
outside the perioperative period (7.0% women, 2.8%
men; P  .245; Table IV, online only). Reoperation was
performed for asymptomatic recurrent carotid stenosis
(80% to 99% with duplex scan) in five men (2.3%) and
two women (1.9%; P  .84).
Stroke-free survival curves were constructed with the
Kaplan-Meier technique. Survival curves were compared
with the log-rank test. Probability of long-term SFS was
reported at 5 years after surgery. Overall probability of SFS
at 5 years was 87% for women and 75% for men (P .584)
(Fig 1). Previously asymptomatic patients had improved
SFS at 5 years (93% female, 85% male; P  .153) (Fig 2).
Patients who had had a prior stroke or TIA had equivalent
5-year SFS rates for both men and women (76%; P .845)
(Fig 3).
Hormone replacement therapy in women. Of 110
women undergoing CEA, 23 (22%) were found to be
undergoing estrogen-based HRT. The perioperative stroke
rate among women with HRT (8.7%) tended to be higher
than among those without (1.2%; P .08). This represents
two perioperative strokes in the HRT group and one stroke







Age (y) 72.6  8.7 70.9  9.2 .104*
Risk factors
Hypertension 86 (75%) 172 (70%) .340
Diabetes 20 (17%) 61 (25%5) .116
Tobacco 67 (58%) 167 (68%) .074
Congestive heart failure 11 (9.6%) 20 (8.1) .650
Myocardial infarction 18 (16%) 58 (24%) .085
Chronic renal failure 5 (4%) 16 (6%) .389
Chronic obstructive pulmonary disease 8 (7%) 16 (7%) .872
Presentation
Symptomatic 57 (50%) 104 (42%) .194
TIA 39 (34%) 68 (28%) .104
Stroke 18 (16%) 36 (14%) .801
Asymptomatic 58 (50%) 142 (58%) .194
Operative characteristics
General anesthesia 115 (100%) 246 (100%) .9†
Electroencephalographic monitoring 98 (85%) 218 (89%) .413
Shunt used 37 (33%) 74 (30%) .667
Patch 101 (89%) 218 (89%) .914
Tacking sutures 0 2 (1%) .9†
*Student t test used for continuous variables.
†Fischer exact test.
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in the no HRT group. Outside the perioperative period,
there was only one new stroke among patients not receiving
HRT, for a 5-year stroke rate of 8.7% HRT and 2.3% no
HRT (P .19; Table V, online only). Probability of SFS at
5 years was roughly equivalent for women undergoing
HRT (84%) compared with those who were not (86%; P
.96) (Fig 4).
DISCUSSION
The ACAS trial established that CEA decreases overall
stroke rate in asymptomatic patients with greater than 60%
carotid stenosis over medical therapy from 11.0% to 5.1%.2
This afforded an overall risk reduction of stroke of 53%.
However, in post hoc analysis, men fared better than
Fig 1. All patients: SFS rate. Probability of SFS at 5 years was not significantly different between men and women after
CEA (Kaplan-Meier method, log-rank test, P  .584).
Fig 2. Asymptomatic patients: SFS rate. Among previously asymptomatic patients, probability of SFS at 5 years was
not significantly different between men and women after CEA (Kaplan-Meier method, log-rank test, P  .153).
JOURNAL OF VASCULAR SURGERY
Volume 37, Number 3 Lane, Shekherdimian, and Moore 571
women, enjoying a 66% risk reduction for men compared
with only a 17% risk reduction for women. In the NASCET
trial, among patients with moderate to severe stenoses3
(50% to 69%), a similar trend in risk reduction was seen (8%
men versus 1% women). Furthermore, regression analysis
identified male gender as being associated with greater
long-term benefit with CEA.
Subsequent to ACAS and NASCET, a number of ret-
rospective trials have been generated to try to validate these
observed gender differences. These include reports from
Northwestern University,13 the University of Mississippi,14
New York University,15 the Cleveland Clinic,16 and Padua,
Italy.17 The largest is from a recent report from the Cleve-
land Clinic in which 3422 CEAs were performed over an
11-year period.16 Univariate analysis showed women to be
at higher risk for postoperative stroke or TIA (3.3% female
versus 2.1% male) and for in-hospital stroke or death (3.1%
female versus 2.1% male). Multivariate analysis showed
female gender to be an independent predictor of perioper-
ative stroke or TIA (odds ratio, 1.7). Because of their large
number of patients, they were able to show significance,
despite small numeric differences in event rates. However,
all of the previously mentioned retrospective studies re-
ported only perioperative results or short-term results in a
small proportion of patients. Therefore, meaningful long-
term comparisons with the randomized trials are not pos-
sible.
In this series, we report an overall perioperative stroke
rate of 3.6% in women and 1.2% in men. In the asymptom-
atic group in our study, there was a 0% perioperative stroke
rate in both men and women. For symptomatic patients,
there was an impressive trend towards an increased periop-
erative stroke rate in women (7.0% female, 2.8% male).
However, because of the intermediate sample size, this
difference failed to reach significance (P .245). Although
this trend toward poorer results in symptomatic women is
compelling, a larger sample size would be necessary to show
statistical significance. Power analysis calculations show
that to detect a 2% difference in these populations with 90%
power would require a sample size of 1184 in each group.
This sample size is exceeded in the Cleveland Clinic review,
and significant gender differences were reported.16 How-
ever, our results fall within the guidelines established by the
Stroke Council of the American Heart Association,12 which
recommend surveillance to maintain perioperative stroke
rates to be less than 3% in asymptomatic patients, less than
5% for patients with prior TIAs, and less than 7% for
patients with prior strokes. Therefore, in our study, CEA
can be performed in all patients who meet ACAS and
NASCET standards with acceptable perioperative out-
come.
Five-year follow-up results in our series support the
assertion that CEA is a durable intervention to reduce
long-term stroke risk. Our overall stroke rate at 5 years was
3.6% for women and 2.0% for men. When only asymptom-
atic patients were considered, there were no new ipsilateral
strokes in women (0%) and only two new strokes in men
(1.4%). Symptomatic patients, although having a higher
perioperative stroke rate (7.0% female versus 2.8% male),
had no new ipsilateral strokes until the time of last follow-
up. Therefore, CEA provided excellent long-term freedom
from stroke in both men and women. Moreover, the long-
term stroke reduction was more profound in the cohort of
women patients because they had no new strokes outside
the perioperative period in our study.
Fig 3. Symptomatic patients: SFS rate. Among patients with preoperative stroke or TIA, probability of SFS at 5 years
was not significantly different between men and women after CEA (Kaplan-Meier method, log-rank test, P  .845).
JOURNAL OF VASCULAR SURGERY
March 2003572 Lane, Shekherdimian, and Moore
Stroke-free survival was also considered in our outcome
analysis. Overall, the probability of stroke-free survival at 5
years was not significantly different in women (87%) and
men (75%; P  .584). When compared separately, asymp-
tomatic patients (93% female, 85% male; P  .153) fared
better than symptomatic patients (76% female, 76% male;
P  .845), without significant gender differences in each
group. The fact that symptomatic patients had poorer
survival may represent an increased severity of systemic
atherosclerotic disease. This is supported by the fact that
there is only a slight increase in the stroke rate after the
perioperative period. Therefore, the cause of death in these
patients must be attributed to a cause other than cerebro-
vascular disease.
Among the female cohort of patients in this study, we
examined the role of HRT in stroke risk and long-term
survival. In the past, estrogen replacement has been
thought to decrease overall mortality and increase 3-year
life expectancy in postmenopausal women.6,18-23 How-
ever, recent studies have called into question the routine
use of HRT in postmenopausal women. The first study to
raise doubts about HRT was seen in a large randomized
control trial, the Heart Estrogen/progestin Replacement
Study,7 which enrolled women with established coronary
vascular disease. Women undergoing HRT were found to
have an increased incidence rate of coronary and thrombo-
embolic events. Most recently, the use of HRT in previ-
ously healthy women was explored in the Women’s Heath
Initiative trial.8 This randomized control trial was halted
after 5.2 years of follow-up because of increased adverse
events in women undergoing HRT, specifically an in-
creased incidence rate of breast cancer and untoward car-
diovascular events. Interestingly, there was a 41% increased
incidence rate of stroke in women undergoing HRT.
The use of HRT in women undergoing CEA has not
been previously explored. There is some evidence of poor
outcome with the use of HRT at the time of vascular
surgical procedures. In a study of femoral-popliteal bypass
grafts in women,9 HRT was found to be the only predictor
of decreased primary patency and was associated with an
increased frequency of graft thrombosis.
In our study, estrogen-based HRT was used in 23 of
104 women (22%). The perioperative stroke rate in women
using HRT (8.7%) tended to be higher than in those that
did not (1.2%). Because of the small sample size, this
difference did not reach statistical significance (P  .08)
and may represent a type II statistical error. The 5-year
stroke rate was 8.7% for women using HRT versus 2.3% for
those who did not. These data suggest that women using
HRT may be at increased risk of stroke in the immediate
postoperative period, with no further increase in risk over 5
years. However, because of our small sample size, these
data are merely suggestive and further studies must be
designed to specifically address this observation. Presently,
we are not asking women to discontinue the use of HRT
before CEA.
Survival data showed an equivalent probability of
5-year SFS in women using HRT (84%) compared with
those who did not (86%). Therefore, our data did not
support the observation of the Heart Estrogen/progestin
Replacement Study study7 that women with established
atherosclerotic disease fared worse than without.
The primary finding in this retrospective study is that
CEA affords both short-term and long-term protection
Fig 4. All women: SFS rate. Among female patients undergoing CEA, probability of SFS at 5 years was not
significantly different between women with HRT and those without (Kaplan-Meier method, log-rank test, P .845).
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against stroke in both men and women. The benefit of CEA
in long-term stroke prevention and improved SFS was
equal, if not better, in women than in men. However, the
risk of perioperative stroke appears to be higher in women
with previous neurologic symptoms and those taking estro-
gen-based HRT.
The weakness of this study is that it is retrospective and
thereby observational in nature. In addition, because of the
limited sample size, it is not powered to determine gender
differences or differences on the basis of the use of HRT.
With regard to subgroup analyses, this study falls victim to
the same pitfalls as the post hoc analyses of the ACAS and
NASCET trials and conclusions on the basis of these ob-
servations should be viewed critically.
We thank Xiao Chen, PhD, for invaluable assistance in
the statistical analysis. We also thank Kamisha Harris, BS,
for work in data collection.
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